FATE - Fate Therapeutics: Data Playing Catchup With Valuation December, 06 2021 02:45 PM Fate Therapeutics Inc. Fate is doing excellent science. It is still valued at $4.58bn. I think that, in the absence of later-stage trial data, this stock is still somewhat overvalued. For further details see: Fate Therapeutics: Data Playing Catchup With Valuation